What is LOPJLB’s current signal on AIM?

LOPJLB’s latest quantitative signal on AIM ImmunoTech Inc. (AIM) is SELL in a CRISIS regime. Signals are updated daily.

What market regime is AIM in?

AIM ImmunoTech Inc. (AIM) is currently classified in the CRISIS HMM market regime on LOPJLB.

What does AIM ImmunoTech Inc. (AIM) do?

AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, a…

AIM ImmunoTech Inc. (AIM)

COMPARE

Healthcare · Biotechnology · AMEX · US

$0.18+0.00%Close

SELLCRISIS · day 30

Company news

globenewswire.com · 7d ago

AIM ImmunoTech's Strategy to Address Immune Resistance in Pancreatic Cancer Featured in BioTuesdays

globenewswire.com · 9d ago

AIM ImmunoTech Highlights Recent Media Coverage of Ampligen's® Broad-Spectrum Antiviral and Biodefense Potential

globenewswire.com · 13d ago

AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data

proactiveinvestors.com · 13d ago

Ionic Rare Earths targets AIM listing as Belfast magnet recycling strategy gathers pace

globenewswire.com · 14d ago

AIM ImmunoTech Discusses Ampligen®'s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video

proactiveinvestors.com · 14d ago

Ondine Biomedical pauses trading to raise fresh investment after positive phase III result

proactiveinvestors.com · 16d ago

1947 Oil & Gas starts AIM trading after £50m fundraising and Gulf acquisition

proactiveinvestors.com · 16d ago

1947 Oil & Gas makes AIM debut with ambitions to grow production sharply in coming years

proactiveinvestors.com · 21d ago

Digitalbox eyes creator-led growth as it rides out Meta disruption

globenewswire.com · 22d ago

AIM ImmunoTech Highlights Ampligen's Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines' Daraxonrasib

proactiveinvestors.com · 23d ago

Shore Capital cheers Coiled Therapeutics dosing progress

proactiveinvestors.com · 23d ago

Coiled Therapeutics fills two cohorts as reworked cancer drug advances

proactiveinvestors.co.uk · 33d ago

Kefi confirms staff safe after fatal Tulu Kapi attack as local investors step up

proactiveinvestors.co.uk · 34d ago

Sintana Energy advances deal to acquire KON-16 in Angola

globenewswire.com · 35d ago

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video

proactiveinvestors.co.uk · 37d ago

Ondine Biomedical strikes deal with Mexico's largest private hospital network

globenewswire.com · 42d ago

AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041

globenewswire.com · 44d ago

AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039

proactiveinvestors.co.uk · 46d ago

Metals One partner rejects claim that Barbrook mine deal has failed

globenewswire.com · 48d ago

AIM ImmunoTech Participates in the Virtual Investor ‘Why Now' On-Demand Conference

Market news & ticker search · RSS for AIM

FAQ

What is LOPJLB’s current signal on AIM?: LOPJLB’s latest quantitative signal on AIM ImmunoTech Inc. (AIM) is SELL in a CRISIS regime. Signals are updated daily.
What market regime is AIM in?: AIM ImmunoTech Inc. (AIM) is currently classified in the CRISIS HMM market regime on LOPJLB.
What does AIM ImmunoTech Inc. (AIM) do?: AIM ImmunoTech Inc., an immuno-pharmaceutical company based in Ocala, Florida, focuses on discovering and advancing treatments for a diverse array of cancers, viral infections, and immune system disorders across the United States. Its primary drug offerings include Ampligen (rintatolimod), a large macromolecular double-stranded ribonucleic acid compound developed for chronic fatigue syndrome, a…

AIM ImmunoTech Inc. (AIM)

Key stats

Prediction markets

Company news

FAQ